Close
28/05/2015
Synchrotron light applications for the pharmaceutical industry
More than forty people from the pharmaceutical sector attended the workshop organised by the ALBA Synchrotron on May 7.

Researchers from the MSPD, CLAESS, XALOC, NCD and MISTRAL ALBA beam lines have shown the available state-of-the-art techniques and the advantages that they offer in this field: fast data acquisition and shorter experiments, cost savings and, in the case of X-ray microscopy, suppression of ethical conflicts because this technique can be a previous step before clinical essays with animals and persons.

The companies Enantia and Almirall, which have already collaborated with the ALBA Synchrotron, have commented their own experiences at the facility. Enantia, specialised in research solutions for other companies, has detailed different examples. For Almirall, the analysis of polymorphic compounds – performed at ALBA – has increased its quality control, verifying and quantifying purity grades.

News based on the press release issued by the ALBA synchrotron.

Image: ALBA synchrotron. Structure of a herpesvirus nuclease-antiviral complex. Data collected at the Xaloc beam line (Bongarzone, S., Nadal, M. & Coll, M., IBMB)

More news

16/09/2014 SENER awarded its first contract with Embraer 09/09/2014 From brick to neuron 02/09/2014 The UAB University is strengthening its position in the Shanghai ranking 27/08/2014 Ascamm develops a drone for rescues 20/08/2014 SENER and ESA reach an agreement for the prime contractor role on the Proba 3 mission 06/08/2014 The Catalan Institute for Nanoscience and Nanotechnology receives the Severo Ochoa accreditation
38 39 40 41 42 43 44 45 46 47 48